BiotechTube
Baxiva

Baxiva

Zug, Switzerland
baxiva.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $28M

Overview

Baxiva is a private, pre-clinical stage biotech startup based in Zug, Switzerland, focused on innovative vaccine development. The company leverages a proprietary platform that chemically conjugates bacterial polysaccharides to virus-like particles (VLPs) to create highly immunogenic, multivalent vaccines against Gram-negative bacteria. Its primary target is E. coli, the leading cause of antibiotic-resistant infections, addressing a critical unmet need in global health. Baxiva is currently pre-revenue and in the early stages of advancing its lead candidate toward clinical development.

Infectious Disease

Technology Platform

Proprietary chemical conjugation platform linking bacterial polysaccharides to virus-like particles (VLPs) for the development of highly immunogenic, multivalent glycoconjugate vaccines against Gram-negative bacteria.

Funding History

1
Total raised:$28M
Series A$28M

Opportunities

The massive and growing global health burden of antimicrobial resistance, particularly from E.
coli, creates a urgent need and a multi-billion dollar market for an effective prophylactic vaccine.
The flexible platform technology allows for rapid expansion into other high-priority Gram-negative pathogens, offering a pipeline-in-a-product opportunity.

Risk Factors

High scientific risk associated with novel vaccine platform technology and unproven clinical efficacy.
Significant financial risk as a pre-revenue startup dependent on external capital in a competitive funding environment.
Intense competition from larger pharmaceutical companies also developing vaccines for resistant bacterial infections.

Competitive Landscape

The field of vaccines for antimicrobial-resistant bacteria is competitive and includes large players like Pfizer, GSK, and Merck, as well as biotechs such as Vaxcyte and LimmaTech Biologics. Differentiation will hinge on the immunogenicity profile, breadth of coverage (serotypes), and development speed enabled by Baxiva's VLP-conjugation platform.

More companies in Biologics / Biosimilars →More companies in Switzerland →